Pre-exposure prophylaxis (PrEP)




HIV Prevention


        


          Scientific Federation proudly invites all the participants from all over the world to attend 2nd International Conference & Expo on HIV & AIDS during Sep 17-18, 2018 in Toronto, Canada.

          In recent research, it found that ageist stereotypes that lead to discrimination and prejudice against older people later it occurs frequently in young and can be seen in children at the age of 3. The most important factor associated ageist stereotypes was the poor quality of contact with grandparents. To assess aspects of ageism the youth were primarily white from urban and rural areas, and from a range of socioeconomic statuses. They also collected information from the youths.

          The World Health Organization (WHO) guidelines on when to start antiretroviral therapy and on pre-exposure prophylaxis (PrEP) for HIV. Qualitative data was sort of health care providers working at the public family planning clinic and other key informants (KIs) working with young women. They were identified by the study staff using local networks to document perspectives on factors influencing young women’s decisions to take up and adhere to PrEP as an HIV prevention strategy.  Textual data coding as a primary qualitative analytical approach was used to summarize, extract meaning and condense the data using Nvivo.

          HIV-AIDS-2018 will provide the excellent opportunities for the researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.

To Know More about Hiv-Aids-2018: Click Here

0 comments:

HIV Revolution on EFDA



HIV REVOLUTION






          Hiv­-Aids research using innovative technology we Scientific Federation proudly organizing 2nd International Conference & Expo on HIV&AIDS which will be held on September 17-18, 2018 at Toronto, Canada.

          In the recent study, an injectable antiretroviral therapy (ART) contains 2 drugs Rilpivirine and Cabotegravir it has to administrate for every 4 or 8 weeks may be as effective as a daily oral dose of the drug in maintaining viral suppression in patients with HIV.

          The Introduction of a single tablet in ART dosing it’s represented a leap forward and it can be long-acting it may represent the next revolution in HIV therapy.

          DR. Hiroshi Ohrui the Professor of the Yokohama University of Pharmacy. He explained about An Extremely Excellent Anti-HIV Nucleosides, 4-C-Ethynyl-2-fluoro-2-deoxyadenosine (EFDA) has attached much attention due to its extremely excellent anti-HIV activity, for example EFDA prevents the emergence of resistant HIV mutants and is over 400 times more active than AZT and several orders of magnitude more active than the other clinical reverse-transcriptase inhibitory 2’,3’-dideoxy-nucleosides drug, very low toxic, very long-acting, very useful for the prevention of HIV-Infection.
For the design of the modified nucleoside which could solve the problems that the clinical drugs have (1. emergence of drug-resistant HIV mutants, 2. The adverse effect of drugs, 3. The necessity to take quite a few amounts of drugs), the following working hypotheses were proposed. They are (1) the way to prevent the emergence of drug-resistant HIV mutants, (2) the way to decrease the toxicity of modified nucleosides, (3) the way to provide the modified nucleoside with stability to both enzymatic and acidic glycolysis for long-acting.

          HIV-AIDS-2018 cordially invites researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.
To Know More about Hiv-Aids-2018: Click Here

0 comments:

EPIDEMIOLOGY AND PREVENTION RESEARCH

                     

                                    EPIDEMIOLOGY AND PREVENTION RESEARCH

         



          Hiv­-Aids research using innovative technology we Scientific Federation proudly organizing 2nd International Conference & Expo on HIV&AIDS which will be held on September 17-18, 2018 at Toronto, Canada.

          The epidemiological context describes whether such risk reduction translates into Measurement of variables describing the epidemiological context, a measurable impact on HIV incidence can be used to tell the local suitability of interventions, The use in the transfer of a successful intervention from one context to another and in scaling up the effort to control HIV infection is explored and These indicators should provide a useful resource for those involved in planning HIV prevention interventions.

          The importance of different levels of indicators, corresponding to programme input, output, outcome, and impact, for the monitoring and evaluation of national HIV/AIDS programmes has recently been clarified. Which are the immediate biological and behavioral determinants of HIV spread, in other words the components of the basic reproductive rate, the efficiency The new method implemented by WHO and UNAIDS is preparing the latest country-specific HIV fact sheets ,WHO and UNAIDS organizations include indicators for proximate determinants, such as  self-reported sexual behavior which includes, non-regular sexual partnerships and context and outcome indicators, age at first sexual encounters, such as condom availability, knowledge of methods of HIV protection, general health service indicators for accessibility and blood safety.

          Of transmission, the rate of exposure of a susceptible to an infectious person, and the duration of infectiousness. It is through these proximate determinants that the impact of the broader socioeconomic context and the output of interventions on HIV incidence are seen.

          HIV-AIDS-2018 cordially invites researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.
To Know More about Hiv-Aids-2018: Click Here

0 comments:

Clinical Research on PWID

                                                                  Clinical Research





          Hiv­-Aids research using innovative technology we Scientific Federation proudly organizing 2nd International Conference & Expo on HIV&AIDS which will be held on September 17-18, 2018 at Toronto, Canada.

          Recently the Clinical research center, they review on the provision of a program to prevent the spread of HIV among the people who inject drugs (PWID). The Global Prevalence of interventions to prevent the spread of the blood-borne virus and of injecting drug among the PWID.  Researchers proved that NSP (needle and syringe programs) and OST (opioid substitution therapy) both can reduce the HIV infection, but many of the places it was not implemented. PWID are living with HIV in risk environment that increases health harms, most of the countries are injecting drug use had NSP and treatment to encourage the reduction in injecting. Scaling up of interventions for people who inject drugs remains a crucial priority of halting the HIV, coverage of HIV prevention interventions for PWID remains poor and insufficient. The greatest prevention benefits are reported when both NSP and OST are implemented in high coverage in combination, recent HIV outbreaks persistently high prevalence among people who inject drugs.

         HIV-AIDS-2018 cordially invites researchers, scientists, professors, delegates and students from all over the world exchange information on HIV-AIDS which contains plenary sessions, keynote speeches, poster, and oral presentations on HIV-AIDS On Emerging area on Immunology, Microbiology, Infection&Imunnity, Public Health, Infectious Diseases, Virology, Pathology, Psychology, Biochemistry, Epidemiology, Gynecology, Global Health, and Population Health.

To Know More about Hiv-Aids-2018 Click Here

0 comments:

Subscribe to: Posts (Atom)